Artificial Intelligence In Diagnostics Market (2026 - 2033) Size, Share & Trends Analysis Report By Component (Software, Hardware, Services), By Diagnosis Type (Cardiology, Oncology, Pathology, Radiology, Chest And Lung, Neurology), By Region, And Segment Forecasts

Artificial Intelligence In Diagnostics Market Summary

The global artificial intelligence in diagnostics market size was estimated at USD 1.97 billion in 2025 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 21.74% from 2026 to 2033. Market growth is driven by advancements in machine learning and deep learning, enabling faster, more accurate diagnostic solutions.

In oncology, cardiology, and neurology, among the areas, the growing demand for early disease detection has led to increased adoption of AI technologies. For instance, in February 2024, Royal Philips introduced the Philips CT 5300, an advanced AI-powered CT system designed for diagnostics, interventional procedures, and screenings. The adaptable X-ray CT system enhances diagnostic accuracy, streamlines workflows, and optimizes system availability.

Rising prevalence of chronic diseases such as diabetes, cancer, cardiovascular disorders, etc., coupled with the increasing demand for early & accurate diagnosis, are significant factors driving market growth. The increasing incidence of cancer globally has led to a growing dependence on AI in the field of oncology. According to the NIH estimates of 2023, approximately 2.0 million individuals in the U.S. are diagnosed with cancer. Breast cancer was the most diagnosed cancer, with an estimated 297,790 cases in women and 2,800 cases in men. Similarly, according to the Centers for Disease Control and Prevention (CDC), 919,032 people died from cardiovascular disease in the U.S. in 2023, equivalent to one in every three deaths.

Such a high prevalence increases the diagnostic workload. Advancements in healthcare IT infrastructure and ongoing technological developments in cloud storage, computing, and machine learning algorithms support the integration of AI-powered systems into diagnostics to provide efficient & accurate diagnoses, allowing care providers to devise timely & appropriate treatment plans. Pathology and radiology services are witnessing a widespread adoption of AI-based algorithms. For instance, in January 2026, Alpenglow Biosciences and PathNet formed a strategic partnership to develop and commercialize 3D AI diagnostic tests for prostate and bladder cancer. The collaboration advances urologic oncology from 2D to 3D pathology in the U.S., integrating imaging, AI analytics, and workflows for enhanced accuracy.

“PathNet’s leadership in urologic oncology, digitization, AI, and strong national footprint make them an exceptional partner as we bring clinical 3D pathology to market. Together, we are building diagnostic tools that deliver insights not achievable with conventional 2D histology.”

- Dr. Nicholas Reder, CEO of Alpenglow Biosciences

In addition, several AI-powered tools are used to diagnose chronic kidney disease (CKD) & kidney function tests, and various chronic diseases. For instance, in May 2024, Premier, Inc. partnered with AstraZeneca to launch the Uncover CKD - Care Collective initiative. The aim is to identify patients with undiagnosed CKD, raise awareness among healthcare providers, and assist U.S. health systems in improving their CKD diagnosis, treatment, and management. Leveraging Premier’s PINC AI technology and services platform, the initiative seeks to address the increasing prevalence of undiagnosed CKD and its associated economic burden on the U.S. healthcare system.

Case Study: Automated Detection and Classification of Bone Marrow Cells

Background and Objective:

• Objective: Automate bone marrow aspirate smear analysis to replace manual differential cell counts.

• Importance: This diagnostic tool aids in detecting hematological conditions by quantifying hematopoietic cells.

Solution Development:

• Model Creation: 20 patient slides with bone marrow aspirates were digitized, pseudonymized, and uploaded to the Aiforia platform.

• Algorithm Training: Aiforia was used to identify nine primary cell types with human validation for accuracy.

• Cloud-Based: Remote accessibility enabled continuous collaboration without software installation.

Outcomes and Benefits:

• Efficiency: Significant reduction in labor-intensive cell counts.

• Future Applications: Potential expansion to other hematopathology areas.

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, levels of partnership & collaboration activities, degree of innovation, impact of regulations, and regional expansion. The AI in the diagnostic industry is consolidated, with the presence of key providers dominating the market. The degree of innovation is high, and the level of merger & acquisition activities is high. The impact of regulations on the industry is high, and the regional expansion of the industry is moderate.

Technological advancements driven by the increasing demand for early and accurate disease detection and by the need to improve patient outcomes further result in significant innovations. For instance, in April 2024, Prenosis, Inc. announced that its Sepsis ImmunoScore received marketing authorization from the U.S. FDA through the De Novo pathway. It is an AI-powered software-as-a-medical-device (AI SaMD) designed to enhance early sepsis diagnosis and prognosis. This marks the first FDA marketing authorization of an AI-based diagnostic tool for sepsis, addressing the longstanding diagnostic challenges posed by this complex condition in the U.S. healthcare system.

The M&A activities, such as mergers, acquisitions, and partnerships, enable companies to expand geographically, financially, and technologically. For instance, in July 2024, GE HealthCare announced the acquisition of Intelligent Ultrasound Group PLC's clinical AI software division for approximately USD 51 million. Intelligent Ultrasound specializes in AI-driven image analysis tools to enhance the efficiency and diagnostic capabilities of ultrasound technology.

The AI in diagnostic industry is significantly affected by regulations, which are overlooked by several regulatory bodies, depending on the region. For instance, in the U.S., the FDA applies its medical device framework, with modifications, through the AI/ML-Based SaMD Action Plan. Similarly, the UK's MHRA advances AIaMD regulation through its 2025 Software and AI as a Medical Device Change Programme, incorporating Regulatory Horizons Council recommendations for lifecycle reforms, regulatory sandboxes with NHS pilots, and enhanced post-market surveillance.

The industry's regional expansion activities in AI in the diagnostic industry are moderate, driven by an increasing demand for AI in the diagnostic industry in the emerging nations. For instance, in May 2025, Niloufer Hospital in Hyderabad launched Amruth Swasth Bharath, India's first AI-powered non-invasive blood test tool by Quick Vitals, using remote PPG for smartphone-based scans. It measures blood pressure, SpO₂, heart rate, HRV, stress, HbA1c, hemoglobin, and cholesterol in 20-60 seconds, without needles, making it ideal for children and pregnant women.

Component Insights

The software solutions segment led the market with the largest revenue share of 46.2% in 2025 and is expected to grow at the fastest CAGR during the forecast period. The segment dominance has been driven by advancements in machine learning algorithms that improve diagnostic accuracy, as well as by the rising demand for efficient, real-time analysis of medical imaging data. It is supported by healthcare providers' increased adoption of AI-driven solutions to streamline workflows and enhance diagnostic precision. For instance, in October 2024, Deepc announced a partnership with the AI Centre for Value-Based Healthcare (AI4VBH) at King's College London and Guy's and St Thomas' NHS Foundation Trust to advance the adoption of radiology AI across the NHS. This collaboration aims to enhance diagnostic speed and accuracy in key areas, including heart failure, dementia, and cancer. Over five years, AI4VBH has developed secure data platforms to support AI model development and deployment, improving access to high-quality electronic health data essential for AI-driven healthcare advancements.

The hardware segment is anticipated to grow at a significant CAGR over the forecast period. The segment growth is primarily driven by the increasing demand for advanced imaging and diagnostic tools that improve patient outcomes and streamline workflows. For instance, in October 2025, Identifeye Health launched an AI-powered retinal camera system for automated diabetic retinopathy screening via eye exams. Enhances access to vision-saving diagnostics, detecting broader health issues early at the point of care without specialists.

Diagnosis Type Insights

The neurology segment led the market with the largest revenue share of 24.15% in 2025. The segment's dominance is attributed to the increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's disease, which necessitate early and accurate diagnosis. Moreover, advancements in AI technologies, particularly in imaging and data analysis, enhance the ability to identify complex neurological conditions, improving patient outcomes. For instance, in August 2024, neurologists from the University of Nebraska Medical Center (UNMC) advanced the field of dementia diagnostics through AI research. This study developed a diagnostic computer model utilizing medical records from 51,269 participants, incorporating data such as exam findings, test results, and MRI scans from nine medical databases. The comprehensive dataset includes information on both common and rare forms of dementia, including Alzheimer's disease and Lewy body dementia.

The oncology segment is expected to grow at a significant CAGR during the forecast period. Cancer diagnosis and treatment have significantly developed over the last decade. The increasing use of technologically advanced solutions for the detection of cancer, mainly at early stages, is contributing to market growth. For instance, in September 2024, Ibex Medical Analytics introduced new advancements to its AI-driven product platform, developed in collaboration with expert pathologists worldwide. The platform's widely deployed AI algorithms, already known for accuracy and robustness in clinical pathology, have been refined using large, diverse datasets and insights from international experts. Validated by live customers and clinical studies, the improved algorithms offer enhanced reliability and versatility across various tissue types, including breast, prostate, and gastric tissues, and can identify numerous tissue morphologies.

Regional Insights

North America dominated the global AI in diagnostics market with the largest revenue share of 54.8% in 2025. Growing government initiatives and business strategies, including mergers & acquisitions, portfolio expansions, collaborations by market players, and funding opportunities by various organizations to promote AI implementation in the diagnostics field, are contributing to the accelerated growth in the region. For instance, in August 2024, the Advanced Research Projects Agency for Health (ARPA-H) introduced a funding opportunity through the Performance and Reliability Evaluation for Continuous Modifications and Usability of Artificial Intelligence (PRECISE-AI) program. This initiative aims to enhance the capabilities of AI tools in clinical settings by enabling the detection of misalignments with their training data and implementing auto-correction mechanisms.

U.S. Artificial Intelligence In Diagnostics Market Trends

The AI in diagnostics market in the U.S. accounted for the largest market revenue share in North America in 2025. The growth is driven by advanced healthcare infrastructure, substantial investment in research and development, and a focus on improving patient outcomes. Moreover, tech companies and healthcare providers' strategic initiatives promote innovation, enhancing diagnostic accuracy. For instance, in October 2024, Invenio Imaging announced that the U.S. FDA granted Breakthrough Device Designation for its NIO Lung Cancer Reveal image analysis module. This module is designed to assist physicians in evaluating bronchoscopic lung forceps biopsies by detecting cell and tissue morphology indicative of cancer in images obtained from fresh, unprocessed biopsy specimens using the NIO Laser Imaging System.

Europe Artificial Intelligence In Diagnostics Market Trends

The AI in diagnostics market in Europe is poised to grow at a significant CAGR over the forecast period. Healthcare systems in Europe are overburdened due to increasing costs, rising incidence of cancer cases, increasing demand for healthcare facilities, and a stagnating or shrinking healthcare workforce. The industry also faces issues due to structural inefficiencies in certain European countries. The move to value-based healthcare is expected to strengthen patient outcomes at a more sustainable cost. Incorporating AI into innovative medical technologies can help address the pressing healthcare issues. In addition, increasing investments in AI in healthcare are driving the market growth.

The UK AI in diagnostics market is expected to grow rapidly over the forecast period. The growth is fueled by government initiatives to modernize healthcare systems and reduce operational costs. Partnerships between healthcare institutions and industry players advance research and enable practical applications of AI technologies. For instance, in October 2024, Optellum announced it had obtained joint funding from the National Institute for Health and Care Research (NIHR) and the Office for Life Sciences (OLS) under a new USD 159.95 million (EUR 148 million) cancer initiative. This funding is to support a study evaluating the effectiveness of its AI product in the early diagnosis of lung cancer.

The AI in diagnostics market in Germany is driven by increasing strategic initiatives undertaken by market players. For instance, in September 2024, Mindpeak collaborated with Roche to integrate its advanced AI algorithms with Roche's Digital Pathology Open Environment. The collaboration enhances cancer diagnostics by advancing clinicians' capabilities, improving patient care, and expanding the reach of personalized medicine solutions.

Asia Pacific Artificial Intelligence In Diagnostics Market Trends

The AI in diagnostics market in Asia Pacific is expected to grow at a substantial CAGR over the forecast period. Increasing patient pool, growing acceptance of cloud computing, and rising number of partnerships & collaborations are among the factors primarily driving the market growth. For instance, in October 2024, Nanyang Technological University and the National Healthcare Group in Singapore announced a partnership to develop voice AI technology and a community intervention program to detect early signs of depression in older people. This initiative seeks to leverage advanced AI capabilities to enhance mental health support for older adults.

The China AI in diagnostics market is poised to grow over the forecast period. China is increasing the use of AI in the healthcare system, rapidly improving disease diagnosis and treatment accuracy in country-level hospitals. For instance, in July 2023, a Hong Kong project secured USD 5 million to leverage AI and genomics for enhanced mental health diagnosis and treatment. This innovative integrated solution transitions from traditional symptom-based methodologies to a data-driven approach, utilizing AI to improve diagnostic accuracy and therapeutic effectiveness.

The AI in diagnostics market in India experiences rapid growth driven by a rising prevalence of chronic diseases such as diabetes and cancer, along with increasing healthcare workforce shortages. For instance, in September 2025, the Punjab Government launched AI-enabled, portable, radiation-free devices for early breast/cervical cancer and vision screening across 8 districts with ACT Grants. Targets 300 cancer and 600 eye screenings daily amid rising cases. Moreover, government initiatives such as Ayushman Bharat Digital Mission and National Digital Health Mission accelerate healthcare digitization, thereby contributing to market growth.

Middle East & Africa Artificial Intelligence In Diagnostics Market Trends

The AI in diagnostics market in the Middle East & Africa is expected to grow significantly over the forecast period. This growth is attributed to increased government initiatives, rapid development of digital infrastructure, and the rising prevalence of chronic diseases. For example, Saudi Arabia’s Vision 2030 and the UAE's Vision 2031 focus on integrating AI into healthcare. Significant funding supports AI-enabled radiology, pathology, and large-scale screening programs to improve diagnostic efficiency and reduce turnaround times. For instance, in December 2025, PureHealth launched the UAE's largest AI-powered standalone diagnostic laboratory in Abu Dhabi, a 70,000 sq ft facility processing over 30 million samples annually across 1,800+ test parameters, including anatomic pathology, molecular genetics, and infectious diseases.

Latin America Artificial Intelligence In Diagnostics Market Trends

The AI in diagnostics market in Latin America is expected to grow at the fastest CAGR over the forecast period. This growth is attributed to the rising prevalence of chronic diseases, increasing government initiatives, and growing adoption of artificial intelligence in healthcare.

Key Artificial Intelligence In Diagnostics Company Insights

Market players are utilizing innovative product development strategies, partnerships, mergers, and acquisitions to expand their presence in response to the increasing demand for early and accurate disease detection, cost containment, addressing the shortage of healthcare providers, and providing value-based care.

Recent Developments

• In November 2025, Philips extended its partnership with Cortechs.ai to integrate NeuroQuant AI analytics directly into Philips MR systems via Smart Reading workflow, enabling zero-click quantitative brain reports for Alzheimer’s, MS, and tumors.

• In May 2025, Diagnostics.ai launched a CE-IVDR-compliant, fully transparent machine learning platform for real-time PCR diagnostics.

"While most diagnostic algorithms remain an impenetrable 'black box,' the PCR.AI API was engineered with transparency included from the ground up. Our platform delivers transparency and traceability that meet and support the highest standards set by CE-IVDR, making the AI decision-making process visible, understandable, and traceable."

-Aron Cohen, CEO of Diagnostics.ai.

• In February 2025, Kauvery Hospitals launched India's first AI-driven Advanced Heart Failure Centre. The center features predictive analytics, IoT monitoring, robotic surgery, TAVR, LVAD/ECMO, and transplants.

• In September 2024, Roche announced the expansion of its digital pathology platform by integrating over 20 advanced AI algorithms from eight new partners. These strategic collaborations are designed to enhance the capabilities of pathologists and scientists in cancer research and diagnosis, utilizing advanced AI technology to improve diagnostic efficiency and accuracy.

"By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide.”

-Jill German, Head of Pathology Lab for Roche Diagnostics

• In July 2024, AWS and GE HealthCare collaborated to enhance healthcare outcomes by leveraging industry-specific AI foundation models (FMs) and innovative applications. This partnership aims to unlock critical healthcare information, paving the way for advanced wellness solutions.

“Health care systems collect large numbers of data points about patients over a lifetime. Unfortunately, very little of it can be accessed efficiently and securely to help inform diagnoses, prognoses, or treatments for patients. Until recently, technology capable of aggregating, analyzing, and interpreting this data securely and efficiently simply didn’t exist.”

~ Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare

• In October 2023, NeuraSignal acquired NovaSignal, the original developer of the NovaGuide system. This robot-assisted transcranial Doppler (raTCD) system operates autonomously during data acquisition, potentially increasing clinicians' access to critical data for detecting right-to-left shunt (RLS).

Artificial Intelligence In Diagnostics Market Report Scope

Global Artificial Intelligence In Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial intelligence in diagnostics market report based on component, diagnosis type, and region:

• Component Outlook (Revenue, USD Million, 2021 - 2033)

  • Software

  • Hardware

  • Services

• Diagnosis Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Cardiology

  • Oncology

  • Pathology

  • Radiology

  • Chest and Lung

  • Neurology

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait